Use of Recombinany DNA, Infectious Organisms, or other potentially Biohazardous marterials

Any use of recombinant DNA (rDNA), infectious organisms, or other potentially biohazardous materials must be reviewed and approved by the Purdue University Institutional Biosafety Committee (IBC) before the use is initiated. The IBC is responsible for reviewing and approving all proposals, activities, and experiments involving an organism or product of an organism that presents a risk to humans. This includes, but is not limited to, work with potential pathogens, work with human clinical samples and primary cell lines and work with DNA from pathogenic organisms. Principal investigators (PIs) must submit to the IBC an application to use rDNA and other biohazards in their research. The IBC review is conducted in accordance with the guidance and requirements of NIH “Guidelines for Research Involving Recombinant DNA Molecules” (NIH Guidelines), the Centers for Disease Control (CDC), Purdue University policies and the Purdue University Biosafety Manual. All PIs have an obligation to be closely familiar with health and safety guidelines applicable to their work and to adhere to them. While certain rDNA protocols are exempt from the NIH Guidelines, a determination of this exemption may only be made by the Chair of the IBC.

Purdue’s Radiological and Environmental Management (REM), the Office of Research Administration (ORA) and the University Biosafety Officer support the IBC in carrying out its responsibilities. Forms for the review of activities involving use of rDNA or other potentially biohazardous materials can be found on the IBC Web site: http://www.purdue.edu/research/vpr/rschadmin/rschoversight/rdna/index.shtml. For further information or assistance, contact the University Biosafety Officer at 49-41496